184 related articles for article (PubMed ID: 29145215)
1. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
le Roux C; Aroda V; Hemmingsson J; Cancino AP; Christensen R; Pi-Sunyer X
Obes Facts; 2017; 10(6):531-544. PubMed ID: 29145215
[TBL] [Abstract][Full Text] [Related]
2. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
O'Neil PM; Garvey WT; Gonzalez-Campoy JM; Mora P; Ortiz RV; Guerrero G; Claudius B; Pi-Sunyer X;
Endocr Pract; 2016 Nov; 22(11):1277-1287. PubMed ID: 27482610
[TBL] [Abstract][Full Text] [Related]
3. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
Ard J; Cannon A; Lewis CE; Lofton H; Vang Skjøth T; Stevenin B; Pi-Sunyer X
Diabetes Obes Metab; 2016 Apr; 18(4):430-5. PubMed ID: 26744025
[TBL] [Abstract][Full Text] [Related]
5. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
7. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
von Scholten BJ; Davies MJ; Persson F; Hansen TW; Madsbad S; Endahl L; Jepsen CH; Rossing P
J Diabetes Complications; 2017 Jul; 31(7):1164-1168. PubMed ID: 28462892
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
10. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
Bays H; Pi-Sunyer X; Hemmingsson JU; Claudius B; Jensen CB; Van Gaal L
Curr Med Res Opin; 2017 Feb; 33(2):225-229. PubMed ID: 27817208
[TBL] [Abstract][Full Text] [Related]
13. Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.
Bensignor MO; Bomberg EM; Bramante CT; Divyalasya TVS; Hale PM; Ramesh CK; Rudser KD; Kelly AS
Pediatr Obes; 2021 Aug; 16(8):e12778. PubMed ID: 33634589
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
[TBL] [Abstract][Full Text] [Related]
15. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
Bensignor MO; Bramante CT; Bomberg EM; Fox CK; Hale PM; Kelly AS; Mamadi R; Prabhu N; Harder-Lauridsen NM; Gross AC
Pediatr Obes; 2023 Sep; 18(9):e13061. PubMed ID: 37264767
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
17. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.
Sharma A; Ambrosy AP; DeVore AD; Margulies KB; McNulty SE; Mentz RJ; Hernandez AF; Michael Felker G; Cooper LB; Lala A; Vader J; Groake JD; Borlaug BA; Velazquez EJ
ESC Heart Fail; 2018 Dec; 5(6):1035-1043. PubMed ID: 30120812
[TBL] [Abstract][Full Text] [Related]
19. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
[TBL] [Abstract][Full Text] [Related]
20. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
